OPKO Health Announces The Appointment Of Greg Stanley As Vice President Of Sales And Marketing For Its Global Diagnostics Business Unit

OPKO Health, Inc. (NYSE:OPK) is pleased to announce the appointment of Greg Stanley as Vice President of Sales and Marketing for its global diagnostics business unit.

Mr. Stanley brings to OPKO extensive experience and expertise in the market development and commercial operations of diagnostic products and services. Prior to joining OPKO, Mr. Stanley served as chief commercial officer of Oncimmune USA, LLC where he led the commercial strategy and market development for the company’s oncology platform in early cancer detection. Most notable was the successful launch and market growth of EarlyCDT®-Lung, the first commercially available blood test to aid in the early detection of lung cancer. Prior to this, Mr. Stanley served over 5 years as director of marketing and then national director of corporate accounts, for Roche Diagnostics where he led the successful market introduction of numerous diagnostic products in point of care, immunodiagnostics, hematology, clinical chemistry, blood gas, urinalysis and blood glucose. Mr. Stanley had increasing scope of responsibility in sales, marketing and management roles at Abbott Diagnostics, Chiron Corporation, and Radiometer prior to his time at Roche. He has been at the executive leadership level for over 15 years and during his tenure served on the board of directors for Radiometer and Oncimmune. Mr. Stanley received his B.S. degree, Business Administration, from the University of Missouri-St. Louis.

“We are excited to have Greg joining the OPKO Diagnostics team here in Miami,” said David Okrongly, President of OPKO Diagnostics. “His experience at launching and gaining reimbursement for novel cancer diagnostic tests combined with his broad background in IVD sales and marketing is the perfect combination for the commercial leadership role in the OPKO Diagnostics business unit.”

“We are fortunate to have Greg join the OPKO Diagnostics team where his commercial expertise will have a significant impact as we prepare for the launch of the 4Kscore™ prostate cancer diagnostic test and the Claros®1 in-office immunodiagnostic analyzer,” said Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer.

ABOUT OPKO HEALTH, INC.

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit http://www.opko.com.

This press release includes forward looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risk and uncertainties that could cause actual results to differ materially from those anticipated. Such statements may relate to our plans, objectives and expected financial and operating results, including statements relating to our products and product development efforts, whether we launch or successfully commercialize the 4Kscore™ prostate cancer test and the Claros®1 in-office immunodiagnostic analyzer, the expected benefits of these and other products in development, as well as other non-historical statements about our expectations, beliefs or intentions regarding business, technologies and products, financial condition, strategies or prospects and other similar statements. The words "may," "could," "would," "will," "believe," "anticipate," "estimate," "expect," "intend," "plan," and similar expressions or variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond our ability to control. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, that compounds or diagnostic products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.